Philippe de Medina

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10213403/publications.pdf

Version: 2024-02-01

43 papers	2,109 citations	257450 24 h-index	265206 42 g-index
43 all docs	43 docs citations	43 times ranked	5593 citing authors

#	Article	IF	Citations
1	Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosomeâ€enriched vesicles. Journal of Extracellular Vesicles, 2022, 11, e12211.	12.2	8
2	Dendrogenin A Enhances Anti-Leukemic Effect of Anthracycline in Acute Myeloid Leukemia. Cancers, 2020, 12, 2933.	3.7	7
3	Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo. Cancers, 2020, 12, 1725.	3.7	13
4	A fast UPLCâ€“HILIC method for an accurate quantiï¬cation of dendrogenin A in human tissues. Journal of Steroid Biochemistry and Molecular Biology, 2019, 194, 105447.	2.5	7
5	The cholesterol-derived metabolite dendrogenin A functionally reprograms breast adenocarcinoma and undifferentiated thyroid cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2019, 192, 105390.	2.5	22
6	HPLC Analysis and Skin Whitening Effects of Umbelliprenin-containing Extracts of Anethum Graveolens, Pimpinella Anisum, and Ferulago Campestris. Molecules, 2019, 24, 501.	3.8	14
7	Deciphering the metabolic secret of longevity through the analysis of metabolic response to stress on long-lived species. Medical Hypotheses, 2019, 122, 62-67.	1.5	3
8	Natural oxyprenylated coumarins are modulators of melanogenesis. European Journal of Medicinal Chemistry, 2018, 152, 274-282.	5.5	22
9	Improvement of 5,6Î±-epoxycholesterol, 5,6Î²-epoxycholesterol, cholestane-3Î²,5Î±,6Î²-triol and 6-oxo-cholestan-3Î²,5Î±-diol recovery for quantification by GC/MS. Chemistry and Physics of Lipids, 2017, 207, 92-98.	3.2	7
10	Quantitative profiling of 4'-geranyloxyferulic acid and its conjugate with l-nitroarginine methyl ester in mononuclear cells by high-performance liquid chromatography with fluorescence detection. Journal of Pharmaceutical and Biomedical Analysis, 2017, 133, 49-55.	2.8	4
11	Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E9346-E9355.	7.1	96
12	Characterization of the Degradation Profile of Umbelliprenin, a Bioactive Prenylated Coumarin of a Ferulago Species. Journal of Natural Products, 2017, 80, 2424-2431.	3.0	13
13	Dendrogenin A drives LXR to trigger lethal autophagy in cancers. Nature Communications, 2017, 8, 1903.	12.8	84
14	Xenohormesis in early life: New avenues of research to explore anti-aging strategies through the maternal diet. Medical Hypotheses, 2017, 109, 126-130.	1.5	2
15	Quantitative analysis of the tumor suppressor dendrogenin A using liquid chromatography tandem mass spectrometry. Chemistry and Physics of Lipids, 2017, 207, 81-86.	3.2	8
16	From tamoxifen to dendrogenin A: The discovery of a mammalian tumor suppressor and cholesterol metabolite. Biochimie, 2016, 130, 109-114.	2.6	21
17	Dendrogenin A and B two new steroidal alkaloids increasing neural responsiveness in the deafened guinea pig. Frontiers in Aging Neuroscience, 2015, 7, 145.	3.4	11
18	The NR4A nuclear receptors as potential targets for anti-aging interventions. Medical Hypotheses, 2015, 84, 135-140.	1.5	33

#	Article	IF	Citations
19	Targeting Cholesterol Homeostasis to Fight Hearing Loss: A New Perspective. Frontiers in Aging Neuroscience, 2015, 7, 3.	3.4	29
20	Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds. Frontiers in Oncology, 2015, 5, 287.	2.8	28
21	The novel steroidal alkaloids dendrogenin A and B promote proliferation of adult neural stem cells. Biochemical and Biophysical Research Communications, 2014, 446, 681-686.	2.1	21
22	5,6-Epoxy-cholesterols contribute to the anticancer pharmacology of Tamoxifen in breast cancer cells. Biochemical Pharmacology, 2013, 86, 175-189.	4.4	56
23	Progesterone and a phospholipase inhibitor increase the endosomal bis(monoacylglycero)phosphate content and block HIV viral particle intercellular transmission. Biochimie, 2013, 95, 1677-1688.	2.6	25
24	Technical note: Hapten synthesis, antibody production and development of an enzyme-linked immunosorbent assay for detection of the natural steroidal alkaloid Dendrogenin A. Biochimie, 2013, 95, 482-488.	2.6	1
25	Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties. Nature Communications, 2013, 4, 1840.	12.8	101
26	Antiestrogen-binding site ligands induce autophagy in myeloma cells that proceeds through alteration of cholesterol metabolism. Oncotarget, 2013, 4, 911-922.	1.8	27
27	MAPK14/p38Î± confers irinotecan resistance to TP53-defective cells by inducing survival autophagy. Autophagy, 2012, 8, 1098-1112.	9.1	79
28	Surprising unreactivity of cholesterol-5,6-epoxides towards nucleophiles. Journal of Lipid Research, 2012, 53, 718-725.	4.2	36
29	Importance of cholesterol and oxysterols metabolism in the pharmacology of tamoxifen and other AEBS ligands. Chemistry and Physics of Lipids, 2011, 164, 432-437.	3.2	51
30	Exosomes account for vesicle-mediated transcellular transport of activatable phospholipases and prostaglandins. Journal of Lipid Research, 2010, 51, 2105-2120.	4.2	528
31	Identification and pharmacological characterization of cholesterol-5,6-epoxide hydrolase as a target for tamoxifen and AEBS ligands. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13520-13525.	7.1	109
32	Auraptene Is an Inhibitor of Cholesterol Esterification and a Modulator of Estrogen Receptors. Molecular Pharmacology, 2010, 78, 827-836.	2.3	50
33	Signaling through cholesterol esterification: a new pathway for the cholecystokinin 2 receptor involved in cell growth and invasion. Journal of Lipid Research, 2009, 50, 2203-2211.	4.2	64
34	Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy, 2009, 5, 1066-1067.	9.1	86
35	Synthesis of New Alkylaminooxysterols with Potent Cell Differentiating Activities: Identification of Leads for the Treatment of Cancer and Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2009, 52, 7765-7777.	6.4	55
36	Microsomal antiestrogen-binding site ligands induce growth control and differentiation of human breast cancer cells through the modulation of cholesterol metabolism. Molecular Cancer Therapeutics, 2008, 7, 3707-3718.	4.1	56

#	Article	IF	Citations
37	Insights into the Cholecystokinin 2 Receptor Binding Site and Processes of Activation. Molecular Pharmacology, 2006, 70, 1935-1945.	2.3	8
38	The Prototypical Inhibitor of Cholesterol Esterification, Sah 58-035 [3-[Decyldimethylsilyl]-N-[2-(4-methylphenyl)-1-phenylethyl]propanamide], Is an Agonist of Estrogen Receptors. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 139-149.	2.5	20
39	Synthesis and Biological Properties of New Stilbene Derivatives of Resveratrol as New Selective Aryl Hydrocarbon Modulators. Journal of Medicinal Chemistry, 2005, 48, 287-291.	6.4	55
40	Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study. Anti-Cancer Agents in Medicinal Chemistry, 2004, 4, 491-508.	7.0	67
41	Molecular Characterization of the Microsomal Tamoxifen Binding Site. Journal of Biological Chemistry, 2004, 279, 34048-34061.	3.4	84
42	Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells. Journal of Pharmacology and Experimental Therapeutics, 2004, 308, 1165-1173.	2.5	71
43	Synthesis, binding and structureâ€“affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS). Bioorganic and Medicinal Chemistry, 2000, 8, 2007-2016.	3.0	27